ISTH Guidelines Bundle (free access)

2020 ISTH TTP Pocket Guideline with GPS

ISTH TTP GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1314283

Contents of this Issue

Navigation

Page 2 of 19

3 ➤ Remarkable advances have been made in recent years towards our understanding of the pathophysiology of thrombotic thrombocytopenic purpura (TTP), which has led to advancements in novel therapies. ➤ Despite an increase in our understandings of pathogenesis of TTP, the approaches for initial diagnosis and management of TTP vary significantly. ➤ The guidelines are intended to support patients, clinicians, and other healthcare professionals in their decisions about the initial diagnosis and management of acute TTP. ➤ In settings with timely access to plasma ADAMTS13 activity testing and for patients with a high clinical suspicion of immune TTP (e.g., based on clinical assessment or a formal clinical risk assessment method), the panel suggests the following diagnostic strategies (See Table 1). (C-L) Table 1. Diagnosis in settings with timely access to plasma ADAMTS13 activity testing and for patients with a HIGH clinical suspicion of immune TTP Step 1. Acquire a plasma sample for ADAMTS13 testing (e.g. ADAMTS13 activity and inhibitors or anti-ADAMTS13 IgG) before an initiation of therapeutic plasma exchange (TPE) or use of any blood product. Step 2. Start TPE and corticosteroids without waiting for the results of ADAMTS13 testing (see Recommendation 1 in Management Guidelines). Step 3. Consider early administration of caplacizumab. (see Recommendation 5 in Management Guidelines) before receiving ADAMTS13 activity results. Step 4. When the result of plasma ADAMTS13 activity is available, continue caplacizumab if ADAMTS13 activity is less than 10 IU/dL (or less than 10% of normal) (a positive result) or stop caplacizumab and consider other diagnoses if ADAMTS13 activity is greater than 20 IU/dL (or greater than 20% of normal) (a negative result). Step 5. For patients with plasma ADAMTS13 activity less than 10 IU/dL (or less than 10% of normal) (a positive result), consider adding rituximab as early as possible, as a majority of these patients (>95%) have autoantibodies against ADAMTS13 (see Recommendation 2 in Management Guidelines). Note: Clinical judgement is required for continuing or stopping treatments (e.g., TPE, corticosteroids, rituximab, and caplacizumab, etc.) when plasma ADAMTS13 activity is between 10 and 20 IU/dL (or 10-20% of normal) (an equivocal result). Diagnosis Key Points

Articles in this issue

view archives of ISTH Guidelines Bundle (free access) - 2020 ISTH TTP Pocket Guideline with GPS